Gilead won US approval for its hepatitis D drug Hepcludex (bulevirtide), four years after the FDA previously rejected the therapy over manufacturing and distribution concerns. The approval follows the agency’s earlier decision that required additional work around manufacturing quality and distribution controls. With the renewed clearance, bulevirtide becomes a key option for chronic hepatitis D management—an area with limited therapeutic reach. For the company, the clearance also closes a major regulatory loop that has delayed access for patients and extended development timelines. For developers of viral-hepatitis treatments, it underscores how FDA focus on supply-chain controls can materially change review outcomes. Overall, the FDA action expands Gilead’s portfolio in viral diseases at a time when hepatitis D remains a clinically urgent gap for many patients worldwide.